Corrigendum to “A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone”

The authors regret that in the original report some figures from previous studies are incorrectly given. The correct figures are as follows

For "The reported rate of pneumonitis in the most comparable trial population namely DESTINY-Breast02 was 6% (25) with two grade 5 deaths (<1%).", read "The reported rate of pneumonitis in the most comparable trial population namely DESTINY-Breast02 was 10% (42) with two grade 5 deaths (<1%)."

For "This intracranial therapeutic effect appears not to be limited to T-DXd, a pre-specified subgroup analysis of HER2CLIMB found in patients receiving tucatinib; the median OS was 21.6 months (95% CI 18.1-28.5 months) for those with BM versus 24.7 months (95% CI 21.6-28.9 months) for those without BM.", read "This intracranial therapeutic effect appears not to be limited to T-DXd, a pre-specified subgroup analysis of HER2CLIMB found in patients receiving tucatinib; the median OS was 21.6 months (95% CI 18.1-28.5 months) for those with BM versus 24.7 months (95% CI 21.6-28.9 months) for those with and without BM."

The authors would like to apologise for any inconvenience caused.